- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
The Impact Of Adherence In Patients With Bipolar I Disorder

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
The Impact Of Adherence In Patients With Bipolar I Disorder
Treatment non-adherence is a dilemma in bipolar disorder and is one of the leading challenges in providing effective treatments for people diagnosed with BP I disorder. During our discussion, Dr. Sajatovic and Dr. Goldberg will discuss and define some of these challenges and provide the latest information on treatment-related determinants of adherence. They will also discuss some of the factors important to adherence.

Martha Sajatovic, MD
Psychiatrist, Director Neurological and Behavioral Outcomes Center, University Hospital Cleveland Medical Center and Professor, Case Western Reserve University School of Medicine
More

Joseph Goldberg, MD
Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai
More

Elizabeth DiNapoli, PhD (OPDC)
Senior Medical Science Liaison
More
Speakers Martha Sajatovic, MD and Joseph Goldberg, MD are paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker Elizabeth DiNapoli, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)